. 2020 Jan 22;10:6. doi: 10.3389/fonc.2020.00006

Table 1.

Comparisons of clinical and imaging characteristics of patients.

Characteristic		Before PSM				After PSM				Effect size
		Chemotherapy + IRE	Chemotherapy	Total number	P value	Chemotherapy + IRE	Chemotherapy	Total number	P value
SEER DATASET
Total number		167	3,348	3,515		167	2,505	2,672
Age (years)	≤60	51	946	997	0.538	51	681	732	0.370	0.002
	>60	116	2,402	2,518		116	1,824	1,940
Gender	Female	78	1,665	1,743	0.476	78	1,251	1,329	0.425	0.001
	Male	89	1,683	1,772		89	1,254	1,343
Race	Black	16	458	474	0.088	16	351	387	0.084	0.005
	White	141	2,583	2,724		141	1,929	2,070
	Others	10	307	317		10	225	235
Tumor size (cm)	≤2	7	120	127	0.778	7	91	98	0.808	0.021
	2~4	71	1,508	1,579		71	1,124	1,195
	>4	89	1,720	1,809		89	1,290	1,379
Tumor grade	Well	15	174	189	0.058	15	140	155	0.051	0.016
	Moderate	74	1,522	1,596		74	1,094	1,168
	Poor	78	1,652	1,730		78	1,271	1,349
LN metastasis	Absent	119	2,189	2,308	0.133	119	1,654	1,773	0.177	0.007
	Present	48	1,159	1,207		48	851	899
Tumor site	Head	84	1,799	1,883	0.473	84	1,352	1,436	0.547	0.024
	Body	53	1,057	1,110		53	772	825
	Tail	30	492	522		30	381	411
Radiotherapy	No	127	2,119	2,246	0.001	127	1,870	1,897	0.783	0.156
	Yes	40	1,229	1,269		40	635	675
SYSUCC DATASET
Total number		36	96	132		36	36	72
Age (years)	≤60	20	52	72	0.887	20	20	40	1.000	0.032
	>60	16	44	60		16	16	32
Gender	Female	17	71	88	0.006	17	24	41	0.153	0.146
	Male	19	25	44		19	12	31
Tumor size (cm)	≤2	1	9	10	0.061	1	1	2	0.256	0.032
	2~4	20	34	54		20	13	33
	>4	15	53	68		15	22	37
Tumor grade	Well	3	1	4	0.092	3	1	4	0.588	0.047
	Moderate	20	56	76		20	21	41
	Poor	13	39	52		13	14	27
LN metastasis	Absent	29	31	60	<0.001	29	29	58	1.000	0.066
	Present	7	65	72		7	7	14
Tumor site	Head	18	45	63	0.001	18	19	37	0.015	0.014
	Body	15	16	31		15	6	21
	Tail	3	35	38		3	11	14
WBC (^*10⁹)	≤10	32	80	112	0.588	32	34	66	0.674	0.037
	>10	4	16	20		4	2	6
HGB (g/L)	≤120	10	25	35	0.828	10	10	20	1.000	0.011
	>120	26	71	97		26	26	52
PLT (^*10⁹)	≤300	31	77	108	0.613	31	30	61	0.743	0.087
	>300	5	19	24		5	6	11
ALT (U/L)	≤40	26	70	96	0.936	26	27	53	0.789	0.092
	>40	10	26	36		10	9	19
AST (U/L)	≤40	29	78	107	0.928	29	31	60	0.753	0.073
	>40	7	18	25		7	5	12
ALP (U/L)	≤100	18	44	62	0.439	19	18	37	0.816	0.071
	>100	18	52	70		17	18	35
GGT (U/L)	≤45	19	37	56	0.166	19	19	38	0.989	−0.001
	>45	17	59	76		17	17	34
ALB (g/L)	≤40	4	42	46	<0.001	4	10	14	0.135	0.110
	>40	32	54	86		32	26	58
TBIL (umol/L)	≤20.5	27	76	103	0.640	27	27	54	1.000	0.013
	>20.5	9	20	29		9	9	18
IBIL (umol/L)	≤15	32	93	125	0.099	32	36	68	0.115	−0.182
	>15	4	3	7		4	0	4
CRP (ng/L)	≤3	24	30	54	<0.001	25	20	45	0.216	0.072
	>3	12	66	78		11	16	27
CEA (ng/mL)	≤5	21	40	61	0.116	21	15	36	0.157	0.175
	>5	15	56	71		15	21	36
CA19-9 (U/ml)	≤35	9	13	22	0.189	9	5	14	0.372	−0.212
	>35	27	83	110		27	30	57
HBsAg	Negative	33	88	121	0.974	33	33	66	1.000	0.003
	Positive	3	8	11		3	3	6
ECGO PS score	0	15	41	56	0.809	15	20	35	0.468	0.165
	1	19	52	71		19	15	34
	2	2	3	5		2	1	3
Chemotherapy	FOLFIRINOX	21	52	73	0.668	22	23	45	0.796	0.087
	Gem	15	44	59		14	13	27

LN, lymph node metastasis; TNM, tumor-node-metastasis stage; WBC, white blood cell count; PLT, platelet count; ALT, alanine transaminase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, glutamyl transpeptidase; ALB, albumin; TBIL, total bilirubin; IBIL, indirect bilirubin; CRP, C-reactive protein; HBsAg, hepatitis B surface antigen; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; HBsAg, hepatitis B surface antigen; ECOG PS, Eastern Cooperative Oncology Group (ECOG) performance status.